MedTrace Logo

The Effects of Nicotinamide Adenine Dinucleotide (NAD) on Brain Function and Cognition

NCT02942888 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2021-09-02

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Niagen (nicotinamide riboside, vitamin B3), on NAD levels, brain function including cognition and blood flow in people diagnosed with mild cognitive impairment (MCI).

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide riboside

Oral administration of Niagen ramp up 250mg to 1g/day as tolerated

DIETARY_SUPPLEMENT

Sugar Pill

This is a placebo compounded by ChromaDex, Inc.

Sponsors & Collaborators

  • University of Texas

    collaborator OTHER

  • South Texas Veterans Health Care System

    collaborator FED

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Becky Powers, M.D. · University of Texas Health Science Center in San Antonio

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-08-31
Completion
2021-08-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02942888 on ClinicalTrials.gov